Hepatitis C in Haematological Patients
Hepatitis Research and Treatment · 2010
DOI: 10.1155/2010/961359 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hepatitis Research and Treatment, 2010. Verfasst von Y Y Hwang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Haematology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0).
Abstract (Originalsprache)
There is no consensus guideline concerning the management of chronic hepatitis C patients during chemotherapy, and immunosuppression. However, there are some suggestions in literature that hepatitis C viral load increases during chemotherapy and there is a risk of rebound immunity against hepatitis C after discontinuation of immunosuppression with a consequent liver injury. A close monitoring of liver function of these patients is prudent during treatment of haematological malignancy. Antiviral treatment is deferred after the completion of chemotherapy and recovery of patients' immunity to minimize the toxicity of treatment. A combination of pegylated interferon and ribavirin is the standard therapy in hepatitis C infected haematological patients.
Autor:innen und Institutionen
- Division of Haematology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Pokfulam, Hong Kong.
Zitieren
APA
Hwang, Y. Y., & Liang, R. H. (2010). Hepatitis C in Haematological Patients. Hepatitis Research and Treatment. https://doi.org/10.1155/2010/961359
Vancouver
Hwang YY, Liang RH. Hepatitis C in Haematological Patients. Hepatitis Research and Treatment. 2010. doi:10.1155/2010/961359
BibTeX
@article{Hwang2010,
author = {Hwang, Y Y and Liang, R H S},
title = {Hepatitis C in Haematological Patients},
journal = {Hepatitis Research and Treatment},
year = {2010},
doi = {10.1155/2010/961359}
}
EUVIMED